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Abstract
Introduction and aim.—Hepatocellular carcinoma (HCC) is the most common type of liver 
cancer in adults and has seen a rapid increase in incidence in the United States. Racial and ethnic 
differences in HCC incidence have been observed, with Latinos showing the greatest increase over 
the past four decades, highlighting a concerning health disparity. The goal of the present study was 
to compare the clinical features at the time of diagnosis of HCC in Latino and Caucasian patients.
Material and methods.—We ret-rospectively screened a total of 556 charts of Latino and 
Caucasian patients with HCC.
Results.—The mean age of HCC diagnosis was not significantly different between Latinos and 
Caucasians, but Latinos presented with higher body mass index (BMI). Rates of hypertension, 
diabetes, and hyperlipidemia were similar in the two groups. The most common etiology of liver 
disease was alcohol drinking in Latinos, and chronic hepatitis C in Caucasian patients. Non-
Alcoholic Steatohepatitis (NASH) was the associated diagnosis in 8.6% of Latinos and 4.7% of 
Caucasians. Interestingly, alpha-fetoprotein (AFP) levels at time of diagnosis were higher in 
Latino patients compared to Caucasians, but this difference was evident only in male patients. 
Multifocal HCC was slightly more frequent in Latinos, but the two groups had similar cancerous 
vascular invasion. Latino patients also presented with higher rates of both ascites and hepatic 
encephalopathy.
Conclusion.—Latino and Caucasian patients with HCC present with a different profile of 
etiologies, but cancer features appear to be more severe in Latinos.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common cancer in men and seventh most 
common cancer in women, and the second leading cause of cancer related deaths.1,2 While 
the high prevalence observed in Asia and Africa is due to the high incidence of hepatitis 
viruses, the rising incidence of HCC in the United States is likely due to non-alcoholic fatty 
liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)3 as well as the high 
prevalence of chronic hepatitis C virus (HCV) infection. The incidence of HCC has more 
than tripled in the United States since the early 1980s4 and, of all types of cancers, has 
shown the greatest increase in mortality.4
Ethnic differences in the incidence of HCC have been described, with higher rates noted in 
Asians, Latinos and African Americans.5–8 In the United States, Latinos have experienced 
the largest increase in HCC incidence over the past 40 years.2,9 Recent analysis of the 
Surveillance, Epidemiology End Result (SEER) found the incidence rates in Latinos to be 
2.5 times higher as compared to White Caucasians.6 These rates are expected to further 
increase, as Latino Americans are the most rapidly growing ethnic minority in the United 
States. Recent immigration patterns indicate Latinos will comprise up to 30% of the total US 
population by the year 2050.10,11 Furthermore, recent studies describe Latinos developing 
HCC at younger ages and having a greater prevalence of metabolic risk factors when 
compared to non-Latino Whites.7,12 The incidence of HCC in Latino men has doubled over 
the past 15 years making the overall rate double that of non-Latino men.13 Mortality rates 
for Latino patients are higher than their Asian and White counterparts despite a higher 
incidence of liver cancer in Asian populations.5,14 Little is known about the presentation and 
features of HCC in Latinos compared to non-Latinos despite the staggeringly high rates and 
mortality due to HCC in the Latino population.
Diabetes mellitus (DM), which is thought to be one risk factor leading to development of 
HCC, has a high prevalence rate in the Latino population.15 Setiawan, et al. studied a 
multiethnic cohort and identified Latinos as the ethnic group at highest risk for developing 
HCC and DM was identified as a risk factor.16 The differences in incidence as well as 
overall survival rate may be secondary to the underlying etiology of HCC. Asians typically 
have higher rates of hepatitis B virus (HBV), while Latinos and Blacks have higher rates of 
HCV, NAFLD, and alcoholic liver disease.17 Venepalli, et al. found Latino patients with 
HCC have a higher incidence of modifiable risk factors, high rates of NASH, and shorter 
overall survival than Caucasian and African American patients.11 Latinos have the greatest 
prevalence of NAFLD18 and higher rates of obesity.19,20 It is likely other ethnic-specific 
differences and genetic factors contribute to the progression of HCC even when the etiology 
of the disease is the same.16
Therefore, identifying the reversible or modifiable risk factors associated with HCC in 
Latinos is critical to begin to bridge the racial disparity gap of HCC. The goal of our study 
was to determine clinical features of HCC at the time of diagnosis in Latino patients as 
compared to non-Latino Whites. A better understanding of ethnic-specific risk factors will 
improve screening and surveillance efforts in this population, as well as possibly identify 
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ethnic-specific treatments which will assist in decreasing the incidence of this deadly cancer 
in a vulnerable population.
MATERIAL AND METHODS
Study population
We performed a retrospective chart review of Latino and non-Latino White patients. All 
patients were identified using electronic medical records from the University of California 
Davis Medical Center in Sacramento, California between 01/01/2008–12/31/2014 using the 
ICD-9 code of HCC. The study was approved by the Institutional Review Board at the 
University of California, Davis Medical Center in Sacramento, CA (IRB # 391877). Of note, 
it has been estimated that 83% of Latinos living in the Sacramento area are Mexican 
Americans.20 We initially identified a total of 556 Caucasian and Latino subjects with a 
diagnosis of HCC. Subjects were excluded from data analysis for the following reasons: 
HCC diagnosis was uncertain or not confirmed (n = 103), HCC diagnosis was, upon further 
review, not entered into the electronic medical record (n = 9), ethnicity was not properly 
described or was other than Latino or White (n = 119) (Figure 1). The final analysis included 
a total of 325 patients with a diagnosis of HCC that were either Latino (n = 70) or Caucasian 
(n = 255).
Data Collection
We used the demographic section of the electronic medical record to identify our research 
population. We collected demographic information on all of our patients: ethnicity 
(quantified as Latino or Not Latino), race (categories included American Indian/Alaska 
Native, Asian, Black/African American, White, more than 1 race, Unknown, Other), 
confirmed diagnosis of HCC (yes or no), age at diagnosis, and Body Mass Index (BMI) at 
diagnosis. We collected clinical and laboratory data at time of HCC diagnosis, including: 
presence and etiology of cirrhosis as determined by imaging via ultrasound, CT scan or MRI 
scan, history of hypertension, diabetes, alpha-fetoprotein (AFP) level, high-density 
Lipoprotein (HDL), triglycerides, creatinine, albumin, alanine transaminase (ALT), total 
bilirubin, presence of ascites and/or hepatic encephalopathy, International Normalized Ratio 
(INR), and from that, calculated Child-Pugh and Model for End-Stage Liver Disease 
(MELD) scores. We also collected data related to HCC features, including which imaging 
modality was used to identify the HCC lesion, if multifocal involvement was present, and 
Milan Criteria and Barcelona Clinic Liver Cancer (BCLC) Score.
Statistical Analyses
Statistical analyses were performed using SPSS Statistics, version 24 (USA) and R statistical 
software, version 3.3.3 (Austria). For continuous data, differences between groups were 
assessed by two-tailed Student’s T-test. For categorical data, differences were assessed by 
Fisher’s exact test. Spearman’s correlation was used to determine correlations among 
continuous variables. Data are presented as mean ± SD. A p-value < 0.05 was considered 
significant.
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RESULTS
The mean age at diagnosis of HCC for Latino patients was 63.4 ± 11.7 years and 61 ± 9.5 
years for Caucasian patients (NS). BMI at presentation was significantly higher in Latino 
patients than Caucasian patients, 30.2 ± 6.6 vs. 28.0 ± 5.6 respectively. In both ethnicities, 
hepatitis C was the most frequent condition associated with cirrhosis, with a higher 
prevalence in Caucasians compared to Latinos. The second most common etiology of liver 
cirrhosis was alcohol abuse in both ethnicities (Table 1).
Among Latino men, alcohol consumption caused a significantly higher proportion of 
cirrhosis (54.9% in Latinos vs. 36.0% in Caucasians, p = 0.021), whereas hepatitis C was the 
most frequent etiology of cirrhosis among Caucasian males, (60.8% in Latino males vs. 
74.1% in Caucasian males, p = 0.048). Comparing Latino males and females, men had a 
significantly higher proportion of cirrhosis from alcohol (54.9% in Latino males vs. 5.3% in 
Latino females, p ≤ 0.001), whereas in Latino women, cirrhosis was due largely to NAFLD 
(3.9% in Latino males vs. 21.1% in Latino females, p = 0.042). Similarly, when comparing 
Caucasian males and females, men had a significantly higher proportion of cirrhosis from 
alcohol as compared to females (36% in Caucasian males and 13.6% in Caucasian females, 
p < 0.001) (Figure 2).
Latinos had higher rates of hypertension and diabetes compared to Caucasians, but the 
difference was not statistically significant. However, Latino females had significantly higher 
rates of diabetes compared to Caucasian females (58% vs. 27% respectively, p = 0.044) 
(Table 1).
Hemoglobin A1c, triglycerides and creatinine were not significantly different between 
ethnicities or sexes. Caucasian females did have significantly higher HDL than their male 
counterparts, (55.1 ± 16.0 vs. 40.2 ± 16.4, p = 0.0076). Albumin, ALT, total bilirubin and 
INR were not significantly different between ethnic groups. Most patients had an INR < 1.7, 
an albumin of between 2.8–2.5 and a total bilirubin < 2.0 (Table 2).
When evaluating features of liver disease, cirrhosis was present in the majority of patients, 
both Latinos and Caucasians. Fatty liver was noted in few patients in our population via 
imaging studies (ultrasound, CT scan, MRI). For ascites and hepatic encephalopathy, it was 
first determined if each manifestation of cirrhosis was present, and if so, if the symptoms 
were controlled with medical therapy or not. The majority of patients did not have ascites, 
and of those that did have ascites, it was largely controlled by the use of diuretics. Only a 
small portion of patients, both Latinos and Caucasians, had uncontrolled ascites when on 
diuretics and Latino females had medication-controlled ascites more frequently than 
Caucasian females (Figure 3). Most patients did not have hepatic encephalopathy, but a 
significantly higher proportion of Latinos had medication-controlled hepatic encephalopathy 
(Figure 3). Most Caucasian patients had a Child-Pugh Class score of A, while most Latinos 
had a score of B (Table 3). MELD scores were not statistically different between sexes or 
ethnicities, although the largest differences were observed between Latino and Caucasian 
females (Table 3).
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When studying the features of HCC lesions, Latino patients had a significantly higher mean 
AFP value, but the result was evident only when comparing Latino and Caucasian men. In 
Latino men, AFP was on average 7 times higher compared to their Caucasian counterpart (p 
= 0.0073). Multifocal involvement was more frequent in Latinos, but the difference was not 
statistically significant. Both ethnic groups had similar rates of cancerous vascular invasion. 
The BCLC scores between the two ethnicities were not statistically different, although 
Latinos were most commonly in the B category, while Caucasian patients were most often in 
the A category (Table 4).
DISCUSSION
HCC is the most common type of liver cancer and has an 84% mortality rate 5 years after 
diagnosis. Ethnic disparities related to HCC presentation and severity have attracted much 
attention in recent years.21 Mortality rates from liver disease and its complications are 
almost 50% higher in Latino patients compared to their non-Latino counterparts, and HCC is 
the sixth most common cause of death in Latinos, whereas it is not in the top ten causes of 
death in Black or Caucasian populations.22,23 More research is being conducted in an effort 
to clarify the factors contributing to this phenomenon and to reduce ethnic-driven health 
disparities. Growing evidence indicates both obesity and diabetes are associated with higher 
rates of developing HCC. While non-Latino diabetics were at higher risk for development of 
HCC than non-diabetics, Latinos had the strongest association between diabetes and 
development of HCC.16
Findings from this single-center retrospective cohort study build on the current literature 
(summerized in table 5) showing that Latinos present with HCC at more advanced stages 
than their Caucasian counterparts. It is currently unclear as to why this is, with a vast 
variation of hypotheses, from socioeconomic factors prohibiting medical care to increased 
risk of metabolic syndrome and associated diseases leading to higher risk of development of 
HCC to cultural factors of waiting longer to visit a health care provider. We found Latinos 
had higher rates of decompensated liver disease, ascites, and hepatic encephalopathy, as well 
as higher Child-Pugh scores. Additionally, Latino patients had higher rates of symptoms of 
decompensated liver disease that were controlled with medical therapy vs. their Caucasian 
counterparts. Ha, et al. demonstrated that although Asians had the highest incidence of HCC, 
they experienced a decrease in overall incidence over recent years, while Latinos 
experienced the greatest increase in HCC incidence.24 AFP levels were also higher in 
Latinos, particularly in Latino men. This is consistent with previous studies showing Latino 
ethnicity was an independent risk factor for HCC-related death, with a worse 5-year survival 
rate when compared to White and Asian counterparts.5,14 Additionally, national data 
indicate a higher prevalence, more advanced features of chronic liver disease, and higher 
liver related mortality in Latino patients.11,23 Unfortunately, there are scant data on the 
features that contribute to or predict different outcomes based on ethnicity.
One of the studies found in the literature review collected similar data to ours, including the 
features of Latino patients at time of presentation of HCC diagnosis. Venepalli, et al. 
demonstrated that Latinos had significantly higher rates of modifiable risk factors of liver 
disease, higher prevalence of NASH and End Stage Renal Disease (ESRD), as well as more 
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advanced liver disease, with higher rates of portal hypertension, ascites, hepatic 
encephalopathy and higher MELD scores.11 Our study confirms many of these findings. 
Latino women were at significantly higher risk of having diabetes. Latinos, and particularly 
women, had almost twice the rates of NASH related liver disease compared to patients of 
other races. Younossi, et al. also showed that Latino ethnicity was an independent risk factor 
for HCC-related mortality, demonstrating a 5-fold higher risk of HCC mortality.14 Prior 
studies have suggested there may be a higher rate of inflammation and aminotransferase 
derangements in Latino patients with NASH than in other ethnic groups, given differing 
metabolic and socioeconomic factors between Latino vs. non-Latino whites.25 Increasing 
evidence demonstrates that diabetes and obesity are independetly associated with increased 
risk of development of HCC. Latino patients have a strong association between these 
diseases and HCC development as compared to non-Hispanics.26 Babalola, et al. confirmed 
that Latino patients had higher rates of metabolic syndrome, but unlike our study, showed 
that they also had higher rates of hepatitis C and were more likely to be female than their 
non-Latino cohort.27 These differences may have been due to the fact that their cohort was 
taken from a teaching hospital in Boston, where the majority of their Latino population is 
Puerto Rican, whereas in our study the majority of our Latino patients are Mexican. 
Setiawan’s longitudinal study also supported the association between metabolic syndrome 
and HCC development, showing diabetic Latino patients had a 3.3x higher risk of HCC 
development as compared to non-diabetic Latinos, with a 2.2x higher risk of HCC in 
diabetic non-Latinos as compared to non-diabetic counterparts.16 Association of metabolic 
syndrome and its related diseases with progression to chronic liver disease in Latinos is of 
great importance, as interventions leading to decreasing these risk factors could possibly 
significantly decrease the incidence of HCC in Latinos, if not all ethnic groups. Furthermore, 
targeted screening of Latinos with these risk factors could lead to earlier diagnosis and 
increased survival rates. While some of the studies that have been performed to date confirm 
several of our results, our study is unique, looking particularly at Latino patients and their 
characteristics at presentation, which has largely not been reported thus far.
One of the major limitations of our study is the relatively small sample size, in particular the 
small number of Latino patients. Additionally, our retrospective cohort design causes biases 
that are associated with this type of study, for example such as the inability to contact 
patients to obtain socio-economic data. Lack of social support and access of needed care 
may influence the time to diagnosis of some of our patients. Furthermore, a single-center 
study in Northern California may not be applicable to all Latino populations. Nevertheless, 
we believe our study provides a comprehensive analysis of disparities that exist between 
Latinos and Caucasians with HCC, particularly alcohol comsumption as well as various 
features of HCC that are more prevalant in Latino patients, such as NAFLD in women, as 
well as Hepatic encephalopathy.
In conclusion, our study provides important data on clinical features of presentation of 
Latinos with HCC. Latino patients present with higher rates of comorbidities and more 
advanced liver disease as compared to their White counterparts, often leading to increased 
mortality from HCC in this ethnic group. This is likely explained by a combination of 
metabolic risk factors, higher rates of NASH cirrhosis and alcoholic cirrhosis as well as 
more aggressive progression of cirrhosis leading to malignancy and death. We further 
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identified that, at least in men, AFP levels are higher in Latino patients, although the 
significance of this is unclear at this time, given the level is more elevated in advanced 
disease, regardless of ethicity. Further prospective studies are needed to collect clinical, 
socio-economic and genetic information on these patients to determine their link to HCC 
severity and reduce the health disparity. It is the hope that with more advanced and directed 
screening of these various risk factors, and determination of which individuals might be at 
higher risk of development of HCC, we can target these patients more carefully and prevent 
development of this deadly cancer.
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ABBREVIATIONS
ALT alanine transaminase
AFP alpha-fetoprotein
BCLC Barcelona Clinic Liver Cancer
BMI body mass index
DM diabetes mellitus
ESRD end stage renal disease
HBV hepatitis B virus
HCV hepatitis C virus
HCC hepatocellular carcinoma
HDL high-density lipoprotein
INR international normalized ratio
MELD model for end-stage liver disease
NAFLD non-alcoholic fatty liver disease
NASH non-alcoholic steatohepatitis
SEER surveillance, epidemiology end result
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Figure 1. 
Selection criteria.
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Figure 2. 
Cirrhosis etiology by ethnicity and sex. Cirrhosis etiology due to alcohol consumption is 
significantly higher in Latino males than in either Caucasian males or Latino females; a 
significantly higher proportion of Latino females had cirrhosis from NAFLD, compared to 
Latino males; significantly more Caucasian males had HCV as the etiology of their cirrhosis 
compared to Latino males; significantly more Caucasian males had alcoholic cirrhosis 
compared to Caucasian females.
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Figure 3. 
Complications of cirrhosis: absence or presence of ascites and hepatic encephalopathy. A. 
Proportion of patients with ascites. Rates of ascites were not statistically different between 
the two ethnic groups. B. Proportion of patients with hepatic encephalopathy. A significantly 
higher proportion of Latino males had hepatic encephalopathy compared to Caucasian 
males; comparing females, rates of hepatic encephalopathy were not different.
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